Following early uterine cancer with tiny cancer cells in nearby lymph nodes
Studies whether tiny cancer cells in lymph nodes near the uterus affect outlook.
Plain-language title generated from the registry record
Registry title: Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
Key facts
- Where
- Montreal and Toronto, CanadaSee the 2 sites
Where in Canada
- Hôpital Maisonneuve-RosemontMontreal, CanadaTaking people
- Sunnybrook Health Sciences, University of TorontoToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06689956
- Record updated
- 19 February 2026
- Original description
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.Read full original descriptionShow less
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective Multicenter Single-Arm Observational Study
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.
Inclusion: Low-risk endometrial cancer, defined as endometrioid, grade 1 or 2, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA (FIGO 2023 stages IA1 and IA2), without substantial/extensive LVSI (≥ 5 vessels involved) at final pathology. Patients with focal LVSI (< 5 vessels involved) will be included; Complete surgical staging, including pelvic sentinel lymph node (SLN) biopsy per National Comprehensive Cancer Network (NCCN) guidelines and ultrastaging; Extent of disease in SLN: ITC (defined as tumor cell aggregates ≤ 0.2 mm or < 200 cells); No adjuvant treatment after surgery; Research consent provided.
Exclusion: Prior neoadjuvant chemotherapy; Planning to receive adjuvant treatment; Presence of synchronous cancer (excluding non-melanoma skin cancer); Extent of disease in SLN: micrometastasis (> 0.2 to ≤ 2.0 mm) or macrometastasis (> 2.0 mm); Presence of substantial/extensive LVSI (≥ 5 vessels involved) at final pathology; Prior invasive cancer diagnosis within 5 years of study entry (excluding non-melanoma skin cancer).